For instance, it strongly inhibits the growth of imatinib-resistant chronic myeloid leukemia (CML) cells, induces DNA damage in these cells, and reduces BCR-ABL transcription levels, thereby curtailing malignant proliferation and transformation without harming normal blood cells (Sun et al., 2016). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.